Clinical trials: Allergen Immunotherapy
Peanut Allergy
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.
- Trial name
- PALISADE (NCT02635776)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 69 sites in United States, Canada and 8 more
- Volunteers
- 555 people
- Sponsor
- Aimmune Therapeutics, Inc.
Allergy
Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients
To compare versus placebo the efficacy and safety of recombinant Bet v1, natural purified Bet v1 and birch pollen licenced extract used for subcutaneous immunotherapy.
- Trial name
- NCT00410930
- Testing
- Subcutaneous immunotherapy - Recombinant birch pollen
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Stallergenes Greer
Seasonal Allergic Rhinitis
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
The objective of this study is to assess the effect of grass pollen extract SLIT tablets on the Rhinoconjunctivitis Total Symptom Score (RTSS) of the six rhinoconjunctivitis symptoms in response to grass pollen challenge after…
- Trial name
- NCT00619827
- Testing
- 300 IR grass pollen allergen extract tablet
- Where
- Austria
- Volunteers
- 89 people
- Sponsor
- Stallergenes Greer
Allergy to Chenopodium Album
Biological Standardization of Chenopodium Album Allergen Extract
The objective of this study is to determine the biologic activity of a Chenopodium album allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01675349
- Testing
- Prick test Chenopodium album allergen extract
- Where
- 2 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Laboratorios Leti, S.L.
Peanut Allergy
A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects
The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.
- Trial name
- V712-103 (NCT03352726)
- Testing
- DBV712 IHRP
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- DBV Technologies
Allergic Rhinoconjunctivitis
Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children
Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering…
- Trial name
- NCT00841256
- Testing
- Grass pollen allergens in a water/glycerol solution
- Where
- Germany
- Volunteers
- 207 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergy
Efficacy and Safety From a Recombinant Folding Variant of Bet v 1
Efficacy and Safety from a recombinant folding variant of Bet v 1
- Trial name
- NCT00554983
- Testing
- recombinant birch pollen allergen
- Where
- Germany
- Volunteers
- 255 people
- Sponsor
- Allergopharma GmbH & Co. KG
Type I-Allergy
Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens
Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)
- Trial name
- NCT00666341
- Testing
- rPhleum
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Allergopharma GmbH & Co. KG
Rhinitis, Rhinoconjunctivitis
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
The purpose of the study is to evaluate the more efficient dose for the treatment of rhinitis/rhinoconjunctivitis against mite allergy
- Trial name
- MM09 (NCT02661854)
- Testing
- MM09 Mannosylated 5.000 subcutaneous, MM09 Mannosylated 10.000 subcutaneous, MM09 Mannosylated 30.000 subcutaneous
- Where
- 14 sites in Spain
- Volunteers
- 186 people
- Sponsor
- Inmunotek S.L.
Allergic Rhinitis
Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
The primary objective is to assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass Subcutaneous Immunotherapy (SCIT) improves upon the efficacy of Timothy Grass SCIT to reduce provoked allergic…
- Trial name
- NCT03558997
- Testing
- Dupilumab, Timothy Grass SCIT
- Where
- 17 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- Regeneron Pharmaceuticals
Allergen Immunotherapy
Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis
This is a Phase 1, first-in-human clinical trial to test a new treatment called ITI-9001 for people with allergies to Japanese Red Cedar (JRC) pollen-a common cause of seasonal allergies in Japan.
- Trial name
- NCT07726147
- Testing
- ITI-9001
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Immunomic Therapeutics, Inc.
Allergy to Alternaria Fungus
To Determine the Minimum Amount of Alternaria Alternata Allergen Extract Producing a Positive Skin Reaction.
The objetive of this study is to determine the minimum amount of Alternaria alternata allergen extract producing in a positive skin reaction.
- Trial name
- NCT01984528
- Testing
- four differente concentrations of Alternaria alternata allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Laboratorios Leti, S.L.
Rhinoconjunctivitis, Grass Allergy
ToleroMune Grass Follow on Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT02292875
- Where
- 2 sites in Canada
- Volunteers
- 84 people
- Sponsor
- Circassia Limited
Cat Allergy
Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT00729508
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Circassia Limited
Rhinoconjunctivitis, Rhinitis
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
- Conditions
- Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
- Trial name
- NCT00550550
- Testing
- SCH 697243, Loratadine Syrup 1 mg/mL Rescue Treatment, Loratadine 10 mg Rescue Treatment
- Volunteers
- 345 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis Due to Grass Pollens
International Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis
The purpose of the present study is to describe patient's perception of quality of life and effectiveness of ORALAIR® over a follow-up period up to 5 years, in real-life settings.
- Trial name
- ALTO (NCT02041624)
- Where
- France
- Volunteers
- 740 people
- Sponsor
- Stallergenes Greer
Rhinoconjunctivitis
ToleroMune House Dust Mites (HDM) Exposure Chamber Study
House Dust Mites (HDM) are arachnids that infest bedding, carpet, upholstered furniture and fabric. Like many other allergens, exposure to HDM allergens in sensitised patients is associated with poorer lung function, greater…
- Trial name
- NCT01447784
- Testing
- ToleroMune HDM
- Where
- Canada
- Volunteers
- 172 people
- Sponsor
- Circassia Limited
Peanut Allergy
AR101 Real-World Open-Label Extension Study
This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.
- Trial name
- NCT03337542
- Testing
- AR101
- Where
- 60 sites in United States, Canada
- Volunteers
- 243 people
- Sponsor
- Aimmune Therapeutics, Inc.
Asthma, House Dust Mite Allergy
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01608243
- Testing
- SLIT tablets of house dust mite allergen extracts
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Stallergenes Greer
Allergy
Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis
Safety and tolerability of ORALAIR in children 5 to 9 years of age during the first 30 days of treatment.
- Trial name
- NCT02295969
- Testing
- Oralair
- Where
- Germany
- Volunteers
- 307 people
- Sponsor
- Stallergenes Greer